NCT03981835: MARS

Management of Antiplatelet Regimen During Surgical Procedures

Completed Last updated 6 February 2026

What this trial tests

trial in Cardiac Surgery in 147 participants. Completed in 30 January 2024.

Timeline

1 August 2019

Primary endpoint
30 January 2024

30 January 2024

Quick facts

Lead sponsor	Baylor Research Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	147
Start date	1 August 2019
Primary completion	30 January 2024
Estimated completion	30 January 2024
Sites	5 locations across United States

Conditions studied

• Cardiac Surgery — all drugs for Cardiac Surgery →
• Surgery — all drugs for Surgery →
• Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
• Surgery--Complications — all drugs for Surgery--Complications →

Sponsor

Baylor Research Institute

Who can join

18 and older, any sex, with Cardiac Surgery or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are key differences today in clinical practice regarding perioperative management of post-PCI patients on DAPT undergoing NCS. Moreover, there are significant differences between bridging agents, and improved safety of current-generation DES. Given the significant limitations of current studies a well-designed registry to study current U.S. practice patterns and the bleeding or ischemic risks associated with the various perioperative DAPT management strategies including bridging and no bridging will significantly add to the understanding of the current problem and associated risks of patients. These data could form the basis for conducting future randomized clinical trials (RCTs) in this area. NCS in post-PCI patients on chronic DAPT presents a complex interaction of both ischemic and bleeding risks.

The MARS registry will study the area of perioperative antiplatelet therapy management through a multicenter observational national registry designed to collect pre-operative, intra-operative and post-operative clinical strategies, therapeutic interventions and outcomes data. This proposal outlines the role of a highly experienced clinical trial team to conduct a multicenter prospective registry. This question is highly relevant to a diverse group of medical providers and millions of patients in the US and around the world; this will be the first such U.S. registry to address this critically important public health issue.

Study objectives:

i. To collect data on contemporary clinical practice in the U.S. on managing post percutaneous coronary intervention (PCI) DAPT in patients scheduled to undergo NCS and CS.

ii. To assess ischemic and bleeding endpoints in this group of patients during the study period.

iii. To generate initial data to plan for future large-scale randomized clinical trials on perioperative management of DAPT.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
   De Luca L, Steg PG, Bhatt DL, Capodanno D, et al · · 2021 · cited 62× · PMID 34212768 · DOI 10.1161/jaha.121.022125
2. Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience.
   Rossini R, Masiero G, Fruttero C, Passamonti E, et al · · 2020 · cited 19× · PMID 33376943 · DOI 10.1055/s-0040-1721504
3. Dual Antiplatelet Therapy with Parenteral P2Y₁₂ Inhibitors: Rationale, Evidence, and Future Directions.
   Alagna G, Mazzone P, Contarini M, Andò G. · · 2023 · cited 8× · PMID 37103042 · DOI 10.3390/jcdd10040163